In Stock Cell Lines
Homo sapiens (Human)
Uterus (cervix)
Adherent
The ATAD1 Knockout Hela Cell Line is a CRISPR/Cas9-edited human cervical adenocarcinoma cell line with targeted disruption of the ATAD1 gene. ATAD1 encodes an AAA+ ATPase that disassembles mitofusin complexes (MFN1/MFN2) on mitochondria and extracts AMPA receptors (GRIA1/GRIA2) at synapses, regulating mitochondrial dynamics and synaptic transmission. This knockout model, in the widely used Hela background, enables mechanistic studies of mitochondrial quality control, mitophagy, and receptor trafficking. Applications include mitochondrial morphology assays, Seahorse metabolic analysis, co-immunoprecipitation for ATAD1-interacting partners, and drug screening for modulators of mitophagy. For additional details, contact Ascent Research.
C20orf27 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG30580
NPEPL1 Knockout Raji Polyclonal Cells
Cat. No. ARG0903
ALOX12 Knockout KYSE150 Polyclonal Cells
Cat. No. ARG36207
LRRC8D Knockout 786-O Polyclonal Cells
Cat. No. ARG4851
OSGIN2 Knockout HEK293T Polyclonal Cells
Cat. No. ARG3739
Mouse Hepatic Fibroblast Medium
Cat. No. ARM0483
The ATAD1 Knockout Hela Cell Line is a CRISPR/Cas9-edited human cell line with targeted disruption of ATAD1 in the Hela cervical adenocarcinoma background. This stable knockout model enables loss-of-function studies of ATAD1, a key regulator of mitochondrial dynamics and synaptic receptor trafficking, without endogenous gene interference.
Hela cells are a widely used human epithelial cell line derived from cervical adenocarcinoma. They are HPV18-positive, resulting in inactivation of p53 and Rb by viral oncoproteins E6 and E7, which facilitates uncontrolled proliferation and provides a well-characterized genetic context. This background is advantageous for investigating mitochondrial function and protein trafficking pathways independent of these tumor suppressors.
ATAD1 encodes an AAA+ ATPase that disassembles mitofusin complexes (MFN1, MFN2) on the mitochondrial outer membrane to prevent hyperfusion and maintains organelle morphology, also facilitating mitophagy. At synapses, it extracts AMPA-type glutamate receptors (GRIA1/GRIA2) from the plasma membrane for lysosomal degradation, regulating excitatory neurotransmission. ATAD1 activity is influenced by cellular energy status, calcium signaling, and kinase cascades. It interacts directly with MFN1, MFN2, GRIA1, GRIA2, and proteasomal components, linking mitochondrial dynamics with synaptic plasticity. Key pathway effectors include OPA1, DRP1, PINK1, and Parkin.
In Hela cells, ATAD1 knockout provides a tractable system to study mitochondrial hyperfusion, cristae disorganization, and impaired mitophagic clearance. Although non-neuronal, these cells express the core mitochondrial fission-fusion machinery, making them suitable for dissecting the mitochondrial functions of ATAD1 without synaptic complexity. The knockout line enables complementation with wild-type or mutant ATAD1 to explore structure-function relationships and allows investigation of metabolic consequences in a cancerous background.
This knockout line supports diverse applications, including MitoTracker staining and live-cell imaging to assess mitochondrial morphology, Seahorse metabolic assays for respiratory function, and co-immunoprecipitation/western blotting to analyze MFN1/MFN2 interactions. In neuronal co-culture systems, it can be used to examine AMPA receptor trafficking via surface biotinylation and electrophysiology. It is also an excellent platform for drug screening to identify mitophagy modulators. For further information or customized requests, please contact Ascent Research.
